Oxycodone/Naloxone Krka (Naloxone Hydrochloride, Oxycodone Hydrochloride)

Naloxone Hydrochloride, the active ingredient in Oxycodone/Naloxone Krka, is an opioid antagonist presented as a combination formulation for oral use. It is used in combination with oxycodone to manage pain while reducing opioid‑induced constipation. GNH USA supplies Oxycodone/Naloxone Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Oxycodone/Naloxone Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Oxycodone/Naloxone Krka is used for moderate to severe pain management where opioid‑induced constipation is a concern.

- Chronic non‑cancer pain: Provides effective analgesia while mitigating constipation. - Cancer‑related pain: Enhances pain control in patients receiving strong opioids. - Post‑operative pain: Controls acute pain after surgery with reduced risk of bowel dysfunction. - Pain associated with severe musculoskeletal disorders: Improves mobility by offering analgesia with bowel‑friendly profile.

Side effects are reported from both components of the combination and may vary in frequency.

Common Side Effects: - Nausea and vomiting - Constipation (less severe than with oxycodone alone) - Dizziness or light‑headed dizziness - Dry mouth - Headache - Somnolence

Serious or Rare Side Effects: - Respiratory depression - Severe hypotension - Acute opioid withdrawal syndrome in opioid‑dependent patients - Hepatic enzyme elevation - Allergic reactions such as rash, pruritus, or anaphylaxis - Seizures (rare)

When prescribing Oxycodone/Naloxone Krka, clinicians should consider several safety aspects.

- Assess pain severity and opioid tolerance: Ensure the patient requires strong opioid therapy. - Monitor for signs of opioid dependence or abuse: Use risk‑mitigation strategies. - Evaluate hepatic and renal function: Dose adjustments may be needed in impairment. - Avoid abrupt discontinuation: Gradual tapering reduces withdrawal risk. - Concomitant CNS depressants: Use with caution due to additive sedation. - Store below 25°C: keep in the original packaging, protect from moisture and light.

Oxycodone/Naloxone Krka may interact with several drug classes; careful review is essential.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (strong h‑ h  ??) -  

Moderate ");